Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: endoceutics.com
Number of Employees: 1
Year Founded: 2006
Total Amount Raised (CAD mm)†: 112.35
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Endoceutics, Inc., a biopharmaceutical company, engages in the research and development of hormone therapies. The company develops acolbifene, for the treatment and prevention of breast cancer; and dehydroepiandrosterone (DHEA), for medical indications affecting postmenopausal women and ageing men. It also develops acolbifene and DHEA in combination as an alternative to traditional hormone replacement therapy for the treatment of vaginal atrophy, muscle mass and strength loss, type II diabetes, obesity, high cholesterol, and bone loss. In addition, the company develops preclinical compounds and non‑estrogen based therapies for the treatment of endocrine-related disorders, including acne, oily skin, male pattern baldness, prostate cancer, and benign prostate enlargement; and a preclinical-stage selective androgen receptor modulator for the treatment of muscle atrophy and bone loss in aging men and women. Further, it provides bioanalytical services for analyzing serum and tissue samples, clinical studies, and intracrinology studies. The company was founded in 2006 and is based in Quebec, Canada. EndoCeutics, Inc. operates as a subsidiary of EndoResearch, Inc.

Financial Information (Currency: CAD, in mm) 
EBIT
(0.1)
Cash & ST Invst.
0.1
Net Income
(0.1)
Total Debt
0.0
Total Assets
2.0


U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Dec-31-2006 TEV and Market Cap are calculated using the last closing price

Key Professionals
Name
Title
Doré, Claude
Chief Financial Officer and Principal Accounting Officer
Dubois, Jean-Denis 
Chief Operating Officer
Émond, Julie-Pascale
Controller

Key Board Members
Name
Title
Després, Robert 
Chairman
Carrière, Serge 
Vice Chairman
Conklin, Donald R.
Director
Archer, David F.
Member of Scientific Advisory Board
Bouchard, Philippe 
Member of Scientific Advisory Board
Dallaire, Michel 
Director
Dupont, Eric
Director
Gallagher, J.C.
Member of Scientific Advisory Board
Gayral, Jean-Pierre
Director
Genazzani, Andrea Riccardo
Member of Scientific Advisory Board
Guillemin, Roger 
Member of Scientific Advisory Board
Howell, Anthony 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
2795 Laurier Boulevard Suite 500 | Québec, QC | G1V 4M7 | Canada
Phone: 418 653 0033   Fax: 418 653 1794

Parent Company
EndoResearch, Inc.

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Bayer Pharmaceuticals Corporation
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Sermonix Pharmaceuticals, Inc.
Sermonix Pharmaceuticals, Inc. operates as a biotechnology company that engages in the development and commercialization of female-specific oncology products. The company also provides treatments for breast cancer. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy (VVA) and the treatment and prevention of postmenopausal osteoporosis. Sermonix Pharmaceuticals, Inc. was formerly known as Sermonix Pharmaceuticals LLC and changed its name to Sermonix Pharmaceuticals, Inc. in July 2019. The company was founded in 2014 and is based in Columbus, Ohio.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-24-2023
May-24-2023
Merger/Acquisition
Seller
Global rights to Intrarosa from Endoceutics, Inc.
Cosette Pharmaceuticals, Inc.
Endoceutics, Inc.
-
Oct-31-2017
Oct-31-2017
Private Placement
Buyer
Sermonix Pharmaceuticals LLC (nka:Sermonix Pharmaceuticals, Inc.)
Endoceutics, Inc.

4.20
Jan-11-2017
Jan-11-2017
Private Placement
Target
Endoceutics, Inc.


85.00
Feb-27-2007
-
Public Offering
Target
Endoceutics, Inc.


51.75
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-24-2023
M&A Transaction Closings
Cosette Pharmaceuticals, Inc. acquired Global rights to Intrarosa from Endoceutics, Inc.
Feb-14-2022
Client Announcements
Theramex Australia Enters Partnership With Endoceutics For Intrarosa® For The Treatment Of Postmenopausal Vulvovaginal Atrophy
Mar-09-2021
Client Announcements
Lupin Pharma to Commercialize Intrarosa in Canada
Nov-06-2019
Product-Related Announcements
Endoceutics Receives Health Canada Approval for INTRAROSA®
May-01-2019
Company Conference Presentations
Endoceutics, Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-01-2019 01:30 PM

M&A Advisors
Borden Ladner Gervais LLP


Advisors
Most Recent Auditor
KPMG Limited
M&A Advisors
Borden Ladner Gervais LLP
Private Placement Advisors
EVOLUTION Life Science Partners
Public Offering Advisors
Eaton & Van Winkle  LLP, Fasken Martineau DuMoulin LLP, KPMG LLP


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 05:45 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Sep 15, 2023 09:59 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Sep 14, 2023 07:15 PM
Endoceutics, Inc.
Endoceutics Inc
Reports
38
GlobalData

Jun 16, 2023 07:52 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Jun 15, 2023 02:10 AM
Endoceutics, Inc.
Endoceutics Inc
Reports
56
GlobalData

Jun 09, 2023 01:03 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
31
GlobalData

Mar 23, 2023 05:01 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21
GlobalData

Mar 16, 2023 03:41 AM
Endoceutics, Inc.
Endoceutics Inc
Reports
52
GlobalData

Mar 10, 2023 03:27 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
31
GlobalData

Dec 27, 2022 03:04 AM
Endoceutics, Inc.
Endoceutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Acolbifene (Future), Acolbifene + DHEA (Future), Dehydroepiandrosterone (Future), Vaginorm (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jun-26-2007
-
Endoceutics, Inc.
SEC
RW
6 KB
May-09-2007
Dec-31-2006
Endoceutics, Inc.
SEC
F-1/A
2 MB
May-02-2007
Dec-31-2006
Endoceutics, Inc.
SEC
F-1/A
2 MB
Apr-25-2007
-
Endoceutics, Inc.
SEC
8-A12B/A
14 KB
Apr-18-2007
-
Endoceutics, Inc.
SEC
8-A12B
14 KB
Apr-18-2007
-
Endoceutics, Inc.
SEC
F-1/A
302 KB
Apr-05-2007
-
Endoceutics, Inc.
SEC
F-1/A
465 KB
Mar-28-2007
-
Endoceutics, Inc.
SEC
F-1/A
2 MB
Mar-16-2007
Jan-31-2006
Endoceutics, Inc.
SEC
F-1/A
2 MB
Feb-27-2007
-
Endoceutics, Inc.
SEC
F-1
3 MB

Key Board Members Details
Name
Title
Phone
Fax
Email
Després, Robert 
Chairman
418 653 0033
418 653 1794

Carrière, Serge 
Vice Chairman
418 653 0033
418 653 1794

Conklin, Donald R.
Director
418 653 0033
418 653 1794

Archer, David F.
Member of Scientific Advisory Board
418 653 0033
418 653 1794
-
Bouchard, Philippe 
Member of Scientific Advisory Board
418 653 0033
418 653 1794

Dallaire, Michel 
Director
(418) 681-6300x247
418 653 1794
-
Dupont, Eric
Director
418 653 0033
418 653 1794
-
Gallagher, J.C.
Member of Scientific Advisory Board
418 653 0033
418 653 1794
-
Gayral, Jean-Pierre
Director
418 653 0033
418 653 1794
-
Genazzani, Andrea Riccardo
Member of Scientific Advisory Board
418 653 0033
418 653 1794
-
Guillemin, Roger 
Member of Scientific Advisory Board
418 653 0033
418 653 1794

Howell, Anthony 
Member of Scientific Advisory Board
418 653 0033
418 653 1794
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Doré, Claude
Chief Financial Officer and Principal Accounting Officer
418 653 0033
418 653 1794
-
Dubois, Jean-Denis 
Chief Operating Officer
418 653 0033
418 653 1794

Émond, Julie-Pascale
Controller
418 653 0033
418 653 1794
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
